The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
The amyloid cascade hypothesis, which posits that the deposition of the amyloid-β peptide in the brain is a central event in Alzheimer's disease pathology, has dominated research for the past twenty years. Several therapeutics that were purported to reduce amyloid-β production or aggregation have failed in Phase III clinical testing, and many others are in various stages of development. Therefore, it is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clinical trials will constitute a valid test of this hypothesis and explore whether amyloid-β-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pathogenetic studies have shown that Aβ peptide accumulation in the brain is an early and central event, 2”
From Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease (2022) · cites this paper as [2]
In the citing paper
“One possible resolution is that amyloid pathology acts only as a trigger in sporadic AD (Karran et al., 2011); i.e., Aβ accumulation is necessary but insufficient to cause full-blown disease.”
From The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques (2019) · cites this paper as Karran et al., 2011
In the citing paper
“since it is known that the Aβ plaques act as a driver of AD pathology63 and the accumulation Aβ plaques in the brain initiates a complex multicellular neurodegenerative process.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [63]
In the citing paper
“The amyloid cascade hypothesis, which dominated the field for over three decades, proposed that the abnormal accumulation of Aβ initiates a downstream cascade leading to tau hyperphosphorylation, synaptic dysfunction, and neuronal death [6, 7].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [7]
In the citing paper
“a possible cause of clinical failure could be the difficulty of inhibiting these proteinases without causing side effects resulting from non-targeted proteolytic inhibition on their many physiological substrates”
From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as Karran et al., 2011
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“The apolipoprotein E ( APOE ) gene represents the major genetic risk factor for A”
BackgroundAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“The discovery that AD could be inherited in an autosomal dominant fashio”
Background
Research works printed but not linked: 2
- Burns, A. & Ilife, S. Dementia. BMJ 338, 405–409 (2009).
- Alzheimer, A. About a peculiar disease of the cerebral cortex. [in German] Centralblatt für Nervenheilkunde Psychiatrie 30, 177–179 (1907).
Cited by
Items 401–500 of 1,007
Phage display derived peptides for Alzheimer's disease therapy and diagnosis
Zhang, X., Zhang, X., Gao, H., & Qing, G. (2022) · Theranostics · doi:10.7150/thno.68636 · Cited by 77
“Among them, extracellular senile plaques (SPs) formed by the deposition of Aβ from amyloid precursor proteins sequentially cleaved by multiple splicing enzymes, and neurofibrillary tangles (NFTs) contributed by the aggregation of intracellular hyperphosphorylated tau proteins are two prominent histopathological hallma…”
BackgroundWu, H., Qiu, W., Zhu, X., Li, X., Xie, Z., Carreras, I., Dedeoglu, A., Dyke, T. E. V., Han, Y. W., Karimbux, N. Y., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.912709 · Cited by 80
“, 2021), which leads to neurodegeneration in the brain (Karran et al., 2011; Yu et al., 2020).”
BackgroundAlzheimer’s Disease and ncRNAs
Maoz, R., Garfinkel, B. P., & Soreq, H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53889-1_18 · Cited by 78
Lipids in Amyloid-β Processing, Aggregation, and Toxicity
Morgado, I., & Garvey, M. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-17344-3_3 · Cited by 71
Gadhave, K., Kumar, D., Uversky, V. N., & Giri, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21719 · Cited by 68
“Next, amyloid cascade hypothesis postulates that the deposition of the amyloid β (Aβ; which is a 39–43 amino acid peptide derived from the amyloid precursor protein [APP] by β‐ and γ‐secretase cleavage) or senile plaques in the brain plays a vital role in the AD pathology.(9,12) In addition to secretase, several prote…”
BackgroundGranzotto, A., Vissel, B., & Sensi, S. L. (2024) · eLife · doi:10.7554/elife.90633 · Cited by 71
“The scheme reports the pillars of the amyloid cascade hypothesis (ACH) left; modified from Karran et al., 2011 .”
Pasciuto, E., Ahmed, T., Wahle, T., Gardoni, F., D’Andrea, L., Pacini, L., Jacquemont, S., Tassone, F., Balschun, D., Dotti, C. G., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.06.032 · Cited by 84
“The formation of b -amyloid (A b 40-42) in the brain is critical for AD progression (Karran et al., 2011; Selkoe, 2002).”
Self-citationLiu, L., Yan, T., Jiang, L., Hu, W. M., Hu, M., Wang, C., Zhang, Q., Long, Y., Wang, J.-Q., Li, Y., et al. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.11 · Cited by 75
Metal-involved theranostics: An emerging strategy for fighting Alzheimer’s disease
Wang, X., Wang, X., & Guo, Z. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.03.010 · Cited by 73
Ruiz-Roso, M. B., Echeverry‐Alzate, V., Ruiz‐Roso, B., Quintela, J. C., Ballesteros, S., Lahera, V., Heras, N. D. L., López‐Moreno, J. A., & Martín‐Fernández, B. (2018) · Nutrients · doi:10.3390/nu11010011 · Cited by 70
“The past 30 years of AD research have produced substantial evidence that accumulation of abnormally folded Aβ and tau proteins in amyloid plaques and neuronal tangles are causally related to neurodegenerative processes in patients’ brains [6].”
BackgroundDual-functional AIE fluorescent probes for imaging β-amyloid plaques and lipid droplets
Wang, Y., Qiu, Y.-T., Sun, A., Xiong, Y., Tan, H.-Y., Shi, Y., Pan, Y. B., Roy, G., Zhang, L., & Yan, J. (2020) · Analytica Chimica Acta · doi:10.1016/j.aca.2020.07.073 · Cited by 72
Bamberger, C., Pankow, S., Martínez-Bartolomé, S., Ma, M., Diedrich, J., Rissman, R. A., & Yates, J. R. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00912 · Cited by 70
The necroptosis cell death pathway drives neurodegeneration in Alzheimer’s disease
Balusu, S., & Strooper, B. D. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02747-5 · Cited by 85
“Aβ plaques [16, 80, 153, 162, 172], being a disease-defining feature of AD, are not directly correlated to neuronal cell death or cognitive decline [16, 51, 79, 80].”
BackgroundResultSelf-citationThe Role of Cholesterol Metabolism in Alzheimer’s Disease
Sun, J.-H., Yu, J.-T., & Tan, L. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8749-y · Cited by 70
Intrinsically Disordered Proteins: Where Computation Meets Experiment
Burger, V., Gurry, T., & Stultz, C. M. (2014) · Polymers · doi:10.3390/polym6102684 · Cited by 84
“Histopathologic analyses of brain tissue derived from post-mortem examinations of patients that suffered from Alzheimer’s disease reveal large inclusions in the neural tissue that are composed of large quantities of amyloid fibrils [165,166].”
BackgroundVisual system manifestations of Alzheimer's disease
Kusne, Y. N., Wolf, A. B., Townley, K., Conway, M. D., & Peyman, G. A. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13319 · Cited by 80
“While the relationship between these two proteins is not clear, both are known to cause pathophysiological effects in experimental models (Selkoe 2002; Karran et al. 2011; Spires-Jones &Hyman 2014).”
BackgroundPenninkilampi, R., Brothers, H. M., & Eslick, G. D. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9722-5 · Cited by 75
Patología vascular: ¿causa o efecto en la enfermedad de Alzheimer?
Rius-Pérez, S., Tormos, A. M., Pérez, S., & Taléns-Visconti, R. (2018) · Neurología · doi:10.1016/j.nrl.2015.07.010 · Cited by 70
“Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.”
Hybrid Multifunctional Modulators Inhibit Multifaceted Aβ Toxicity and Prevent Mitochondrial Damage
Rajasekhar, K., Mehta, K., & Govindaraju, T. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00033 · Cited by 69
Oleuropein aglycone and hydroxytyrosol interfere differently with toxic Aβ1-42 aggregation
Leri, M., Natalello, A., Bruzzone, E., Stefani, M., & Bucciantini, M. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.04.015 · Cited by 77
Candelise, N., Scaricamazza, S., Salvatori, I., Ferri, A., Valle, C., Manganelli, V., Garofalo, T., Sorice, M., & Misasi, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116016 · Cited by 78
Drosophila Models of Alzheimer's Disease: Advances, Limits, and Perspectives
Bouleau, S., & Tricoire, H. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-142802 · Cited by 69
“These failures do not fully rule out the amyloid cascade hypothesis [7], since most of the trials have been performed on patients with mild or advanced stages of the disease.”
Gut Microbiota Influences Alzheimer’s Disease Pathogenesis by Regulating Acetate in Drosophila Model
Kong, Y., Jiang, B., & Luo, X. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0185 · Cited by 69
Modulation of γ- and β-secretases as early prevention against Alzheimer's disease
Voytyuk, I., De Strooper, B., & Chávez-Gutiérrez, L. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.001 · Cited by 67
“Of notice, the therapeutic strategy of BACE1 inhibition in AD is entirely based on a purely quantitative interpretation of the amyloid hypothesis (6, 11), in which higher Aβ production is pathogenic.”
Exploring the Role of PSEN Mutations in the Pathogenesis of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Setu, J. R., Ashraf, G. M., Bin-Jumah, M. N., & Abdel‐Daim, M. M. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00232-x · Cited by 78
Addressing Blood–Brain Barrier Impairment in Alzheimer’s Disease
Sharma, C., Woo, H., & Kim, S. R. (2022) · Biomedicines · doi:10.3390/biomedicines10040742 · Cited by 68
“Although the pathways linking Aβ and tau are not clearly understood, the amyloid cascade indicates that changes in tau and the consequent formation of NFTs are triggered by toxic concentrations of Aβ [90].”
BackgroundCdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses
Wilkaniec, A., Czapski, G. A., & Adamczyk, A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13365 · Cited by 67
“methods based on an anti-Ab approach have not yielded satisfactory results (Hardy and Higgins 1992; Hardy and Selkoe 2002; Karran et al. 2011; Armstrong 2014).”
BackgroundMethodPeptides as Potential Therapeutics for Alzheimer’s Disease
Ribarič, S. (2018) · Molecules · doi:10.3390/molecules23020283 · Cited by 67
Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
Lalli, G., Schott, J. M., Hardy, J., & De Strooper, B. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114781 · Cited by 67
“On the other hand, there is also compelling evidence that a simplistic cause–consequence relationship between accumulating amyloid and neurodegeneration should have been abandoned more than a decade ago (Karran et al, 2011).”
BackgroundSelf-citationEmerging Mechanisms and Targeted Therapy of Ferroptosis in Neurological Diseases and Neuro-oncology
Wang, Y., Tang, B., Zhu, J., Yu, J., Hui, J., Xia, S., & Ji, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72251 · Cited by 75
“At present, the pathogenesis of AD is still unclear, and the most accepted hypothesis is the amyloid cascade hypothesis, that is, the main pathological feature of AD is the deposition of amyloid beta peptide in the brain leading to the death of nerve cells [89, 90].”
BackgroundPark, S. J., Jung, J. M., Lee, H. E., Lee, Y. W., Kim, D. H., Kim, J. M., Hong, J. G., Lee, C. H., Jung, I. H., Cho, Y.-B., et al. (2012) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2012.07.019 · Cited by 73
Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
Giovanni, G. D., Štrac, D. Š., Solé, M., Unzeta, M., Tipton, K. F., Mück‐Šeler, D., Bolea, I., Corte, L., Perković, M. N., Pivac, N., et al. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00541 · Cited by 84
“, 2011), glutamate/calcium neurotoxicity (Karran et al., 2011), and hyperphosphorylated tau protein (Li et al.”
BackgroundChen, Y., Lin, H., Yang, H., Tan, R. X., Bian, Y., Fu, T., Li, W., Wu, L., Pei, Y., & Sun, H. (2017) · RSC Advances · doi:10.1039/c6ra25887e · Cited by 68
Amyloid β-Targeted Metal Complexes for Potential Applications in Alzheimer's Disease
Liu, H., Qu, Y., & Wang, X. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0248 · Cited by 79
Neuromodulatory Effects of Guanine-Based Purines in Health and Disease
Tasca, C. I., Lanznaster, D., de Oliveira, K. A., Fernández‐Dueñas, V., & Ciruela, F. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00376 · Cited by 78
Zhang, H., Zhao, Y., Yu, M., Zhao, Z., Liu, P., Cheng, H., Ji, Y., Jin, Y., Sun, B., Zhou, J., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.008 · Cited by 69
Okello, E. J., & Mather, J. (2020) · Nutrients · doi:10.3390/nu12041090 · Cited by 76
Alzheimer’s disease: where next for anti-amyloid therapies?
Hardy, J., & De Strooper, B. (2017) · Brain · doi:10.1093/brain/awx059 · Cited by 67
“In the third scenario, Aβ is proposed to be only a trigger of the disease process (Karran et al. , 2011).”
BackgroundInfluentialSelf-citationPresenilin controls kinesin-1 and dynein function during APP-vesicle transport in vivo
Gunawardena, S., Yang, G., & Goldstein, L. S. B. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt237 · Cited by 66
Jackson, H. M., Soto, I., Graham, L. C., Carter, G. W., & Howell, G. R. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-831 · Cited by 66
“Attempts to develop new treatments for AD have proven unsuccessful [11-16] which likely highlights the lack of”
BackgroundMukhopadhyay, S., & Banerjee, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215065 · Cited by 66
“…the amyloid cascade hypothesis incorporates several key pathogenic points in the process of AD and provides a practical explanation for the phenotypes, it falls short of accounting for the A (cid:2) interaction with tau, which is a central factor for the downstream neuronal damage in AD [17].”
Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story
Stamford, A. W., & Strickland, C. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.04.016 · Cited by 73
PET molecular imaging for pathophysiological visualization in Alzheimer’s disease
Wang, J., Jin, C., Zhou, J., Zhou, R., Tian, M., Lee, H. J., & Zhang, H. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05999-z · Cited by 76
“Once the balance of Aβ metabolism is damaged, toxic conformations of Aβ would emerge and trigger pathological processes [95, 96].”
BackgroundPharmacotherapy of Alzheimer’s disease: current and future trends
Geldenhuys, W. J., & Darvesh, A. S. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.990884 · Cited by 67
“The key hallmark of AD pathogenesis is the accumulation of neuritic plaques formed of amyloid-b (Ab) peptide, derived from amyloid precursor protein (APP) as well as neurofibrillary tangles made up of hyperphosphorylated protein [2].”
Backgroundde Matos, A. M., de Macedo, M. P., & Rauter, A. P. (2018) · Medicinal Research Reviews · doi:10.1002/med.21440 · Cited by 66
Chen, C., Liang, Z., Zhou, B., Li, X., Lui, C., Ip, N. Y., & Qu, J. Y. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00306 · Cited by 69
Yao, J., Sun, B., Institoris, A., Zhan, X., Guo, W., Song, Z., Liu, Y., Hiess, F., Boyce, A. K. J., Ni, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108169 · Cited by 65
“amyloid (Aβ) plaques in the brain (Berridge, 2010; Hardy and Selkoe, 2002; Karran et al., 2011).”
BackgroundHypometabolism, Alzheimer’s Disease, and Possible Therapeutic Targets: An Overview
Raut, S., Bhalerao, A., Powers, M., Gonzalez, M., Mancuso, S., & Cucullo, L. (2023) · Cells · doi:10.3390/cells12162019 · Cited by 65
“These peptides have the potential to accumulate into plaques in the spaces between neurons, which are observed in the brains of AD patients [172,173].”
BackgroundDistinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease
Kljajević, V., Grothe, M. J., Ewers, M., & Teipel, S. J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.04.006 · Cited by 70
“Unlike neuro fi brillary tangles of misfolded tau-protein, another key neuropathological feature of AD, b -amyloid plaques show only weak association to neuronal loss or dementia severity and do not correlate with the disease duration (Karran et al., 2011).”
Diagnostic imaging of Alzheimer's disease with copper and technetium complexes
Hickey, J. L., & Donnelly, P. S. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.035 · Cited by 73
Krishnan, R., Tsubery, H., Proschitsky, M., Asp, E., Lulu, M., Gilead, S., Gartner, M., Waltho, J. P., Davis, P. J., Hounslow, A. M., et al. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.04.015 · Cited by 66
“A variety of therapies targeting specific protein aggregation pathways, such as those for amyloid-β, the microtubule-associated protein tau and pre-synaptic protein α-synuclein, are in all stages of drug development, and these drug candidates include vaccines, monoclonal antibodies (MAbs), antisense oligonucleotides a…”
BackgroundRozpedek, W., Markiewicz, L., Diehl, J., Pytel, D., & Majsterek, I. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150818104254 · Cited by 65
“The Amyloid Cascade Hypothesis explains that pathogenesis of AD is associated with the presence of Aβ42 in senile plaques which are the results of the above-mentioned mutations that finally lead to cell death through the destruction of nerve cells and symptoms of dementia [7, 8].”
BackgroundVan Dam, D., Vermeiren, Y., D. Dekker, A., J.W. Naudé, P., & P. De Deyn, P. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160502123607 · Cited by 65
Zafeiris, D., Rutella, S., & Ball, G. (2018) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.02.001 · Cited by 72
“Karran et al. [25] have attempted to update the hypothesis for use in therapeutics by presenting four distinct scenarios describing the role of A β in AD.”
Backgroundβ-Amyloid Induces Pathology-Related Patterns of Tau Hyperphosphorylation at Synaptic Terminals
Wu, H.-Y., Kuo, P.-C., Wang, Y.-T., Lin, H.-T., Roe, A. D., Wang, B. Y., Han, C.-L., Hyman, B. T., Chen, Y.-J., & Tai, H.-C. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly059 · Cited by 64
“There is growing evidence that the interaction between Ab and tau pathology is critical for AD pathogenesis (3, 4, 57, 58), but it has been very difficult to elucidate when, where, and how they interact in the brain during the natural history of AD.”
BackgroundHepcidin and its therapeutic potential in neurodegenerative disorders
Qian, Z., & Ke, Y. (2019) · Medicinal Research Reviews · doi:10.1002/med.21631 · Cited by 65
Sivilia, S., Lorenzini, L., Giuliani, A., Gusciglio, M., Fernández, M., Baldassarro, V. A., Mangano, C., Ferraro, L., Pietrini, V., Baroc, M. F., et al. (2013) · BMC Neuroscience · doi:10.1186/1471-2202-14-44 · Cited by 70
“These include active and passive anti-Aβ vaccines, but also γ-secretase inhibitors and modulators, and Aβ aggregation inhibitors [4-7].”
BackgroundMonitoring the Formation of Amyloid Oligomers Using Photoluminescence Anisotropy
Jiang, B., Aliyan, A., Cook, N. P., Augustine, A., Bhak, G., Maldonado, R., McWilliams, A. D. S., Flores, E., Méndez, N., Shahnawaz, M., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b06966 · Cited by 65
Neuroprotective Effect of Caffeine in Alzheimer’s Disease
Yelanchezian, Y. M. M., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2022) · Molecules · doi:10.3390/molecules27123737 · Cited by 75
“The pathophysiology of AD is based on the accumulation of abnormally folded Aβ and Tau proteins in amyloid plaques and neuronal tangles that contribute to neurodegeneration in patients’ brains [3].”
BackgroundJiang, M., Gan, Y., Li, Y., Qi, Y., Zhou, Z., Fang, X., Jiao, J., Han, X., Gao, W., & Zhao, J. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126153 · Cited by 67
Soldano, A., Okray, Z., Janovska, P., Tmejová, K., Reynaud, E., Claeys, A., Yan, J., Atak, Z. K., De Strooper, B., Dura, J.-M., et al. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001562 · Cited by 64
“The amyloid cascade hypothesis has also dominated the search for AD treatments, but the promising molecular candidates developed to modulate the Ab peptide and reached clinical trials failed [34,35].”
Self-citationRole of Tau Protein in Neuronal Damage in Alzheimer's Disease and Down Syndrome
Cárdenas, A. M., Ardiles, Á. O., Barraza, N., Báez‐Matus, X., & Caviedes, P. A. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.012 · Cited by 80
The epigenetic dimension of Alzheimer's disease: causal, consequence, or curiosity?
Millan, M. J. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.3/mmillan · Cited by 63
Chiquita, S., Ribeiro, M., Castelhano, J., Oliveira, F., Sereno, J., Batista, M., Abrunhosa, A., Rodrigues-Neves, A. C., Carecho, R., Baptista, F., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz045 · Cited by 63
S-Nitrosylation in Alzheimer's disease
Zhao, Q., Yu, J., & Tan, L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8672-2 · Cited by 67
“However, recent phase III clinical tests fail to therapeutically modify AD progression via the inhibition of β-amyloid cascade targets [107, 108].”
Shiao, Y., Su, M., Lin, H., & Wu, C. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040895 · Cited by 62
“production of Aβ, preventing Aβ oligomerization, promoting Aβ degradation, and counteracting Aβ cytotoxicity [2].”
BackgroundInfluentialYuan, C., Li, S., Zou, Q., Ren, Y., & Yan, X. (2017) · Physical Chemistry Chemical Physics · doi:10.1039/c7cp01923h · Cited by 63
Modulating 5-Ht 4 and 5-Ht 6 Receptors in Alzheimer’S Disease Treatment
Lalut, J., Karila, D., Dallemagne, P., & Rochais, C. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0031 · Cited by 67
Fišar, Z., Hansíková, H., Křížová, J., Jirák, R., Kitzlerová, E., Zvěřová, M., Hroudová, J., Wenchich, L., Zeman, J., & Raboch, J. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.07.013 · Cited by 75
Mallucci, G. R., Klenerman, D., & Rubinsztein, D. C. (2020) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-040320-120625 · Cited by 62
Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimer’s Disease
Oyarzún, M. P., Tapia-Arellano, A., Cabrera, P., Jara-Guajardo, P., & Kogan, M. J. (2021) · Sensors · doi:10.3390/s21062067 · Cited by 65
“Among the biomarkers that are currently known for AD diagnosis, the most relevant one is the Aβ peptide, showing a key participation in the development of AD, as described in the amyloid cascade hypothesis [4,18,19] shown in Figure 2A.”
BackgroundPassive immunotherapy for Alzheimer's disease
Guo, X., Li, Y., Zhang, D., & Zhao, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102192 · Cited by 78
“A β has long been the major focus of efforts to develop passive immunotherapy for AD (Karran et al., 2011).”
Design and Synthesis of a Novel Series of Bicyclic Heterocycles As Potent γ-Secretase Modulators
Bischoff, F., Berthelot, D., Cleyn, M. A. J. D., Macdonald, G. J., Minne, G., Oehlrich, D., Pieters, S., Surkyn, M., Trabanco, A. A., Tresadern, G., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201710f · Cited by 64
Self-citationAmyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer’s Disease
Morsy, A., & Trippier, P. C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01530 · Cited by 70
Sleep–wake regulation and the hallmarks of the pathogenesis of Alzheimer’s disease
Van Egroo, M., Narbutas, J., Chylinski, D., Villar González, P., Maquet, P., Salmon, E., Bastin, C., Collette, F., & Vandewalle, G. (2019) · Sleep · doi:10.1093/sleep/zsz017 · Cited by 62
(ADNI), A. D. N. I., Kleineidam, L., Chouraki, V., Próchnicki, T., van der Lee, S. J., Madrid-Márquez, L., Wagner-Thelen, H., Karaca, I., Weinhold, L., Wolfsgruber, S., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02138-6 · Cited by 62
Does hearing loss lead to dementia? A review of the literature
Nadhimi, Y., & Llano, D. A. (2020) · Hearing Research · doi:10.1016/j.heares.2020.108038 · Cited by 71
Kidana, K., Tatebe, T., Ito, K., Hara, N., Kakita, A., Saito, T., Takatori, S., Ouchi, Y., Ikeuchi, T., Makino, M., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708184 · Cited by 61
“Thus, understanding the molecular mechanism of brain “Ab economy” (Karran et al, 2011), which reflects the balance of the rates of production, clearance, and aggregation of Ab, is crucial for the development of effective therapeutics for AD.”
BackgroundAbdullah, S. A., Najm, L., Ladouceur, L., Ebrahimi, F., Shakeri, A., Al‐Jabouri, N., Didar, T. F., & Dellinger, K. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202302673 · Cited by 68
BACE1 as a Therapeutic Target in Alzheimer’s Disease: Rationale and Current Status
Evin, G., & Hince, C. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0099-3 · Cited by 52
Findeis, M. A., Schroeder, F. C., McKee, T. D., Yager, D., Fraering, P. C., Creaser, S. P., Austin, W., Clardy, J., Wang, R., Selkoe, D. J., et al. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn3000857 · Cited by 64
Watanabe, K., Uemura, K., Asada, M., Maesako, M., Akiyama, H., Shimohama, S., Takahashi, R., & Kinoshita, A. (2015) · Molecular Brain · doi:10.1186/s13041-015-0174-2 · Cited by 62
“The amyloid cascade hypothesis posits that the deposition of the Aβ peptide in the brain parenchyma initiates a sequence of events that ultimately leads to dementia [17].”
BackgroundPicone, P., Vilasi, S., Librizzi, F., Contardi, M., Nuzzo, D., Caruana, L., Baldassano, S., Amato, A., Mulè, F., San Biagio, P. L., et al. (2016) · Aging · doi:10.18632/aging.101004 · Cited by 61
“From a molecular point of view, the overproduction and aberrant self-assembly of the amyloid β peptide (Aβ) into fibrillar aggregates constitute the first step of the so-called amyloid cascade hypothesis, thought to trigger AD [29].”
BackgroundTimmers, M., Van Broeck, B., Ramael, S., Slemmon, J., De Waepenaert, K., Russu, A., Bogert, J., Stieltjes, H., Shaw, L. M., Engelborghs, S., et al. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.08.001 · Cited by 60
“Multiple lines of evidence support the amyloid cascade hypothesis stating that Ab accumulation and deposition are the initiating factors for the pathogenesis of AD [3,4].”
BackgroundSelf-citationZhang, Z.-X., Li, Y., & Zhao, R. (2016) · Neurochemical Research · doi:10.1007/s11064-016-2093-8 · Cited by 67
Sakamoto, K., Matsuki, S., Matsuguma, K., Yoshihara, T., Uchida, N., Azuma, F., Russell, M., Hughes, G., Haeberlein, S. B., Alexander, R. C., et al. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.950 · Cited by 61
Mastinu, A., Premoli, M., Ferrari‐Toninelli, G., Tambaro, S., Maccarinelli, G., Memo, M., & Bonini, S. A. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2018-0013 · Cited by 70
Wang, X., Xu, W., Chen, H., Li, W., Li, W., & Zhu, G. (2020) · Brain Research · doi:10.1016/j.brainres.2020.147041 · Cited by 63
Fuller, O. K., Whitham, M., Mathivanan, S., & Febbraio, M. A. (2020) · Cells · doi:10.3390/cells9102182 · Cited by 60
The interaction with gold suppresses fiber-like conformations of the amyloid β (16–22) peptide
Bellucci, L., Ardèvol, A., Parrinello, M., Lutz, H., Lü, H., Weidner, T., & Corni, S. (2016) · Nanoscale · doi:10.1039/c6nr01539e · Cited by 66
Mertens, J., Stüber, K., Wunderlich, P., Ladewig, J., Kesavan, J. C., Vandenberghe, R., Vandenbulcke, M., van Damme, P., Walter, J., Brüstle, O., et al. (2013) · Stem Cell Reports · doi:10.1016/j.stemcr.2013.10.011 · Cited by 60
Landlinger, C., Oberleitner, L., Gruber, P., Noiges, B., Yatsyk, K., Santic, R., Mandler, M., & Staffler, G. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0369-6 · Cited by 68
“showed consistent improvements in AD patients (reviewed in [5, 6]).”
ResultSerrano‐Pozo, A., Aldridge, G. M., & Zhang, Q. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170184 · Cited by 64
“Although there is currently a sense in the AD research community that the research efforts should be shifted from Aβ to tau, in part motivated by the failure of anti-Aβ directed clinical trials to substantially impact the rate of cognitive decline [75, 76], this shift is not yet reflected in PubMed.”
Long-term RF exposure on behavior and cerebral glucose metabolism in 5xFAD mice
Son, Y., Kim, J. S., Jeong, Y. J., Jeong, Y. K., Kwon, J. H., Choi, H., Pack, J., Kim, N., Lee, Y., & Lee, H. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.12.042 · Cited by 63
Coniferaldehyde attenuates Alzheimer's pathology via activation of Nrf2 and its targets
Dong, Y., Stewart, T., Bai, L., Li, X., Xu, T., Iliff, J. J., Shi, M. Y., Zheng, D., Yuan, L., Wei, T., et al. (2019) · Theranostics · doi:10.7150/thno.36722 · Cited by 63
“Hence, treating AD at early stages and targeting processes upstream of AD pathogenesis, such as amyloid β (Aβ) deposition to prevent the onset of AD pathology in the brain, might be a more desirable strategy [8-12].”
BackgroundQiang, L., Fujita, R., & Abeliovich, A. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.002 · Cited by 59
“For instance g-secretase inhibitors, such as semagacestat, are highly effective in transgenic models of AD, but failed in human studies (Karran et al., 2011).”
Li, Y., Wang, K., Zhou, K., Guo, W., Dai, B., Liang, Y., Dai, J., & Cui, M. (2018) · Chemical Communications · doi:10.1039/c8cc05259j · Cited by 59
Huang, Y., Cho, H.-J., Bandara, N., Sun, L., Tran, D., Rogers, B. E., & Mirica, L. M. (2020) · Chemical Science · doi:10.1039/d0sc02641g · Cited by 74
Paul, R. K., Mazumder, M. K., Nath, J., Deb, S., Paul, S., Bhattacharya, P., & Borah, A. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104823 · Cited by 68
Guzmán, B. C., Chaffey, T. E., Palpagama, T. H., Waters, S., Boix, J., Tate, W. P., Peppercorn, K., Dragunow, M., Waldvogel, H. J., Faull, R. L. M., et al. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.552073 · Cited by 70
Metadata
- Authors
- Karran, E., Mercken, M., & Strooper, B. D.
- Affiliations
- Janssen (Belgium) (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- Corresponding author
- Karran, Eric
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-08-19
- Volume
- 10
- Issue
- 9
- Pages
- 698-712
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2079749054
- Cited by
- 2,188
- References
- 157
- Citations by year
- 2026: 74 · 2025: 115 · 2024: 130 · 2023: 139 · 2022: 141 · 2021: 158 · 2020: 174 · 2019: 191 · 2018: 174 · 2017: 163 · 2016: 171 · 2015: 160 · 2014: 151 · 2013: 130 · 2012: 107
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- amyloid hypothesis, Alzheimer's disease, amyloid-beta, amyloid-beta aggregation, amyloid-beta production, clinical trial design, phase III trial failure, drug development
- MeSH terms
- Alzheimer Disease, Animals, Brain Chemistry, Humans, Research Design, Amyloid beta-Peptides, Treatment Failure, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Age of Onset, Disease Progression, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.